myeloablative therapy and was recently found to inhibit smooth muscle cells proliferation and arterial 23 thrombus formation in the mouse by preventing tissue factor (TF), a key activator of the coagulation cas- 24 cade. This study was designed to investigate whether DMSO prevents platelet activation and thus, 25 whether it may represent an interesting agent to be used on drug eluting stents. Methods and results: 26 Human venous blood from healthy volunteers was collected in citrated tubes and platelet activation 27 was studied by cone and platelet analyzer (CPA) and rapid-platelet-function-assay (RPFA). CPA analysis 28 showed that DMSO-treated platelets exhibit a lower adherence in response to shear stress 29 (À15.54 ± 0.9427%, n = 5, P < 0.0001 versus control). Additionally, aggregometry studies revealed that 30 DMSO-treated, arachidonate-stimulated platelets had an increased lag phase (18.0% ± 4.031, n = 9, 31 P = 0.0004 versus control) as well as a decreased maximal aggregation (À6.388 ± 2.212%, n = 6, 32 P = 0.0162 versus control). Inhibitory action of DMSO could be rescued by exogenous thromboxane A2 33 and was mediated, at least in part, by COX-1 inhibition. Conclusions: Clinically relevant concentrations 34 of DMSO impair platelet activation by a thromboxane A2-dependent, COX-1-mediated effect. This finding 35 may be crucial for the previously reported anti-thrombotic property displayed by DMSO. Our findings 36 support a role for DMSO as a novel drug to prevent not only proliferation, but also thrombotic complica- 37 tions of drug eluting stents. 38 
Introduction

42
Arterial thrombosis is the crucial event in a large number of car-43 diovascular conditions such as acute coronary syndromes (ACS) 44 [6, 19] . Even though coronary bare metal stents (BMS) and drug 45 eluting stent (DES) implantation greatly improved prognosis of 46 ACS patients, acute and sub-acute stent thrombosis still remain a 47 serious concern [4, 5, 14, 15, 17, 20, 31, 34] . In line with this, we re-48 cently showed that drugs released from DES enhance tissue factor 49 (TF), a key trigger for thrombosis and thus could play a paradoxical 50 role in eliciting stent thrombosis [29, 32] . In this context, DMSO 51 could represent an interesting alternative drug which not only 52 inhibits human vascular smooth muscle cell (HVSMC) prolifera-53 tion, but also prevents TF expression and thrombus formation 54 in vivo [6] . 55 Initiation of a luminal thrombosis involves both activation of 56 the coagulation cascade by TF and factor VII [18, 22, 23, 33] , and 57 platelet activation [13, 26] . Under normal circumstances, platelets 58 do not aggregate spontaneously; however, in the event of an in-59 jury, platelets adhere to the disrupted surface and release different 60 biologically active substances which induce aggregation [13] . 61 Abnormal platelet activation is implicated in a wide variety of car-62 diovascular disorders [1, 3, 16, 20, 28, 36] crease of light transmittance due to platelet agglutination [25] .
99
The test was performed according to the manufacturer's instruc- via inhibition of COX-1 (Fig. 3) . 
U N C O R R E C T E D P R O O F
195 molecular insights [6, 8] . In this study, we for the first time can 196 clearly demonstrate that DMSO inhibits platelet adherence and 197 platelet aggregation which are essential steps for the physiological 198 and pathophysiological formation of a stable occlusive thrombus 199 [24] . Thrombus formation is the key process in stent thrombosis, Fig. 3 . DMSO inhibits COX-1 activity. DMSO 0.5% significantly decreased total COX activity (n = 5, P = 0.0455) compared to control. Similarly, COX-1 inhibitor SC-560 caused a comparable inhibition of total COX activity (n = 5, P = 0.0107) compared to control. Co-incubation of DMSO and SC-560 caused no further decrease in COX activity (n = 5, P = NS) compared to DMSO alone. reducing systemic treatment associated risks and costs [20, 35] . 
